Double-blind RCT testing whether scheduled intra-articular triamcinolone slows or worsens structural knee osteoarthritis. 140 patients with symptomatic knee OA and ultrasound synovitis received 40 mg triamcinolone or saline every 12 weeks for 2 years. Serial MRI quantified cartilage volume; WOMAC tracked pain.
When a patient with knee osteoarthritis asks for repeated steroid shots, this trial gives you the counseling point: scheduled triamcinolone every 3 months for 2 years accelerated cartilage loss and did not relieve pain better than saline.
This reframes corticosteroid injection as a short-term symptomatic tool, not a disease-modifying or maintenance therapy. The AAOS guideline already gives intra-articular steroids only inconclusive support, and this RCT explains why scheduled use is not justified.
The mechanistic lesson is high-yield: OA is an inflammatory disease driven by synovitis, yet suppressing inflammation with steroids did not slow structural progression and instead unmasked the catabolic effect of corticosteroids on cartilage.
One appraisal caveat matters for boards. Pain was measured every 3 months, not in the first 4 weeks after injection when steroids work best, so the trial was designed to detect long-term, not transient, benefit. Bottom line for practice: reserve steroid injections for episodic flare control and do not commit patients to a recurring injection schedule expecting joint protection.
Double-blind RCT testing whether scheduled intra-articular triamcinolone slows or worsens structural knee osteoarthritis. 140 patients with symptomatic knee OA and ultrasound synovitis received 40 mg triamcinolone or saline every 12 weeks for 2 years. Serial MRI quantified cartilage volume; WOMAC tracked pain.
When a patient with knee osteoarthritis asks for repeated steroid shots, this trial gives you the counseling point: scheduled triamcinolone every 3 months for 2 years accelerated cartilage loss and did not relieve pain better than saline.
This reframes corticosteroid injection as a short-term symptomatic tool, not a disease-modifying or maintenance therapy. The AAOS guideline already gives intra-articular steroids only inconclusive support, and this RCT explains why scheduled use is not justified.
The mechanistic lesson is high-yield: OA is an inflammatory disease driven by synovitis, yet suppressing inflammation with steroids did not slow structural progression and instead unmasked the catabolic effect of corticosteroids on cartilage.
One appraisal caveat matters for boards. Pain was measured every 3 months, not in the first 4 weeks after injection when steroids work best, so the trial was designed to detect long-term, not transient, benefit. Bottom line for practice: reserve steroid injections for episodic flare control and do not commit patients to a recurring injection schedule expecting joint protection.